Mary Beth Harler

Mary Beth Harler is President of Pioneering Medicines, Flagship Pioneering’s in-house drug discovery and development unit, dedicated to conceiving and developing a broad portfolio of life-changing treatments for patients built from Flagship’s innovative platforms.

Mary Beth joined Flagship after serving as CEO of IGM Biosciences, a clinical-stage biotechnology company focused on engineered IgM antibodies. Before becoming CEO, she led research, CMC/manufacturing, and autoimmunity and inflammation at IGM. She was previously with Bristol Myers Squibb (BMS) for over 10 years, where she most recently served as SVP, Head of Autoimmunity, Inflammation, and Fibrotic Diseases. Prior to this role, she served as the Head of Innovative Medicines Development at BMS, with oversight of Phase 1 – 4 clinical development programs across a range of therapy areas, including autoimmunity, fibrotic, and cardiovascular diseases. Mary Beth previously worked at Wyeth Pharmaceuticals (now Pfizer) in clinical research and medical affairs, with particular focus on autoimmune and inflammatory disorders.

Trained as a general surgeon at Brown University’s Rhode Island Hospital, Mary Beth was also a research fellow with a focus on the role of immune cells in wound healing. She received her B.Sc. from Wheeling University and her M.D. from the Marshall University Joan C. Edwards School of Medicine.